| Identification | Back Directory | [Name]
p2Ca peptide | [CAS]
142606-55-1 | [Synonyms]
p2Ca
p2Ca peptide
H-Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu-OH
L-Leucine, L-leucyl-L-seryl-L-prolyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-α-aspartyl- | [Molecular Formula]
C47H66N8O12 | [MDL Number]
MFCD10567373 | [MOL File]
142606-55-1.mol | [Molecular Weight]
935.07 |
| Chemical Properties | Back Directory | [Boiling point ]
1307.2±65.0 °C(Predicted) | [density ]
1.298±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [pka]
3.24±0.10(Predicted) | [Water Solubility ]
Soluble in Water | [Sequence]
Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu |
| Hazard Information | Back Directory | [Uses]
p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C. | [in vivo]
BALB/c mice, coinjected with a syngeneic BALB/c myeloma and exogenous p2Ca, are able to reject the tumor. The p2Ca/L d system may thus provide a model for evaluating the parameters for effective immunotherapy with tumor-associated peptides[3]. | [storage]
Store at -20°C | [References]
[1] Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14. DOI:10.4049/jimmunol.167.8.4207
[2] Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6. DOI:10.1073/pnas.91.24.11482
[3] Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8. PMID:7505197 |
|
| Company Name: |
Ontores Biotech
|
| Telephone: |
0571-88760729 18072970094 |
| Website: |
www.ontoresinc.cn |
| Company Name: |
Combio (Suzhou) Ltd.
|
| Telephone: |
17751201929; 17751201929 |
| Website: |
http://www.combiosz.com/ |
|